These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 11368288)

  • 1. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
    Santini V
    Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
    Spencer CM; Goa KL
    Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifostine in clinical oncology: current use and future applications.
    Koukourakis MI
    Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J; Küttner K; Fröhlich D; Glatzel M
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
    De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
    Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
    Capizzi RL; Oster W
    Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
    J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.